GlassScriptPhysician profile
Rocio Pestana
NPI 1316068612
$5,655.21
in general payments reported to CMS, 2019-2025
28 companies · $680 in 2025
The $680 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $794 · 2020: $825 · 2021: $874 · 2022: $749 · 2023: $754 · 2024: $979 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,413.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,182.22 | 2019-2025 | Farxiga, Airsupra |
| Abbvie INC. | $626.02 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $608.54 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $525.06 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $439.62 | 2019-2025 | |
| Novo Nordisk INC | $434.22 | 2019-2025 | Wegovy |
| Allergan, INC. | $420.09 | 2019-2020 | |
| Glaxosmithkline, LLC. | $268.57 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $223.60 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.69 | 2019-2025 | Xifaxan |
| Amgen INC. | $89.73 | 2019 | |
| Merck Sharp & Dohme LLC | $84.47 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.11 | 2019-2020 | |
| Inspire Medical Systems, INC. | $67.49 | 2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $61.58 | 2022-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $51.18 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.12 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.70 | 2022 | |
| Currax Pharmaceuticals LLC | $47.77 | 2020-2021 | |
| Amarin Pharma, INC. | $46.18 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $42.48 | 2022-2023 | Quviviq |
| Vertical Pharmaceuticals, LLC | $40.94 | 2019 | |
| Eisai INC. | $30.72 | 2021 | |
| Abbott Laboratories | $22.67 | 2023 | Eterna |
| Ibsa Pharma INC. | $21.29 | 2024 | Licart, Tirosint |
| Genentech USA, INC. | $19.15 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $18.23 | 2019 | |
| Saluda Medical Americas, INC. | $13.77 | 2025 | Evoke |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rocio Pestana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.